Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Clearmind doses first patient in trial of MEAI-based treatment for AUD

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that the first patient has been dosed in its Phase 1/2a clinical trial of its proprietary MEAI-based oral drug candidate, CMND-100, for the treatment of alcohol...

July 2, 2025

Developments

Medical City Dallas Hospital enhances surgical precision with Perimeter’s OCT imaging technology

Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced that Medical City Dallas Hospital—an award-winning, 899-bed acute care hospital in the Dallas-Fort Worth area—has adopted the company’s current...

July 2, 2025

Executive Moves

Dr. Robert T. Foster appointed to the Order of Canada

Dr. Robert T. Foster Her Excellency the Right Honourable Mary Simon, Governor General of Canada, has announced 83 new appointments to the Order of Canada, including Robert Thomas Foster, PharmD, PhD, C.M., A.O.E. Dr...

July 1, 2025

Developments

KalVista grants Pendopharm rights to commercialize sebetralstat for HAE

KalVista Pharmaceuticals (NASDAQ: KALV) has announced that it has entered into a licensing agreement with closely held Pendopharm to manage the regulatory approval process and commercialization of sebetralstat, an...

June 26, 2025

Developments

NMPA approves Theravance’s YUPELRI for COPD in China

Theravance Biopharma (NASDAQ: TBPH) has announced that China’s National Medical Products Administration (NMPA) has granted regulatory approval for YUPELRI, the company’s revefenacin inhalation solution for the treatment...

June 26, 2025

Developments

Clearmind adds leading Israeli clinical site to ongoing trial of CMND-100 in AUD

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that it has added Tel Aviv Sourasky Medical Center (TASMC) to the list of clinical sites for its ongoing Phase 1/2a trial evaluating CMND-100—a proprietary MEAI...

June 24, 2025

Developments

Immunic reports positive long-term OLE data from trial of IMU-838 in RRMS

Immunic (NASDAQ: IMUX) has announced new, positive long-term open-label extension (OLE) data from its Phase 2 EMPhASIS trial of lead asset, orally available nuclear receptor-related 1 (Nurr1) activator, vidofludimus...

June 24, 2025

Executive Moves

Medicus appoints Andrew Smith as COO

Medicus Pharma (NASDAQ: MDCX) has announced the appointment of Andrew Smith as chief operating officer (COO). A seasoned leader in asset management and financial operations with more than three decades of experience, Mr...

June 23, 2025

Executive Moves

Kevin DeGeeter rejoins Ladenburg Thalmann as managing director of biotechnology equity research

Ladenburg Thalmann announced that Kevin DeGeeter has rejoined the firm as a managing director in its equity research department, effective June 2025. In this role, Mr. DeGeeter will lead equity research coverage of...

June 23, 2025

Developments

ArriVent reports encouraging data from firmonertinib monotherapy study in NSCLC

ArriVent BioPharma (NASDAQ: AVBP) announced encouraging additional follow-up proof-of-concept data from its global Phase 1b FURTHER trial of first-line firmonertinib monotherapy in patients with non-small cell lung...

June 23, 2025

Developments

Compass Pathways meets primary endpoint in Phase 3 trial of psilocybin for TRD

Compass Pathways (NASDAQ: CMPS) announced that it has achieved the primary endpoint in the first of two ongoing Phase 3 trials evaluating COMP005 psilocybin for treatment-resistant depression (TRD). The ongoing Phase 3...

June 23, 2025

Developments

Firefly uncovers powerful new method of measuring SCD, MCI, and dementia in Alzheimer’s disease

Firefly Neuroscience (NASDAQ: AIFF) has announced a significant advancement in Alzheimer’s disease research: the company has identified a novel, objective method for measuring and distinguishing between subjective...

June 20, 2025

Subscribe